Elimination of FK-506 by continuous hemodiafiltration in a liver transplant patient.
A liver transplant patient who developed renal failure postoperatively was treated using continuous hemodiafiltration (CHDF). Doses ranging from 0.01 to 0.06 mg/kg/day of FK-506 had been administered intravenously. FK-506 concentrations before and after the filter, and in the ultradiafiltrate were 45.3 +/- 2.9, 56.0 +/- 5.3, and 9.1 +/- 3.1 ng/ml (mean, +/- S.D.), respectively. The filtration rate was 23.6 +/- 6.4%, and extracted FK-506 amounted to 522.0 micrograms (11.3% of administered dose). A part of the FK-506 administered was eliminated through the filter during CHDF.
Tsubo
T
T
Intensive Care Unit, University of Hirosaki School of Medicine, Aomori-ken, Japan.
Iwakawa
T
T
Muraoka
M
M
Ishihara
H
H
Matsuki
A
A
D058186:Acute Kidney Injury / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D000328:Adult; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control; D017583:Hemodiafiltration; D006801:Humans; D007166:Immunosuppressive Agents / Q000032:analysis / Q000493:pharmacokinetics* / Q000627:therapeutic use; D007275:Injections, Intravenous; D007362:Intensive Care Units; D007668:Kidney / Q000503:physiopathology; D016031:Liver Transplantation / Q000009:adverse effects* / Q000276:immunology; D011183:Postoperative Complications; D016559:Tacrolimus / Q000032:analysis / Q000493:pharmacokinetics* / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D016559:Tacrolimus